• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

April 17, 2015
CenterWatch Staff

Kenneth C. Frazier, chairman and CEO of Merck, was elected chairman of the board of the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). At the board meeting, PhRMA’s president and CEO John J. Castellani announced he will be retiring Jan. 1, 2016. 

Frazier formerly held the position of chairman-elect and succeeds Ian C. Read, chairman and CEO of Pfizer. Also elected were George A. Scangos, Ph.D., CEO of Biogen, as chairman-elect of the PhRMA board of directors, and Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, as board treasurer.

Before becoming chairman and CEO of Merck in 2011, Frazier was president of Merck with responsibility for the company’s three major divisions: Global Human Health, Merck’s sales and marketing division for pharmaceutical and vaccine products; Merck Manufacturing, the company’s manufacturing and supply division; and Merck Research Laboratories, Merck’s research organization. Previously, he was president of Merck Global Human Health from 2007 to 2010 and as general counsel, overseeing Merck’s legal and public affairs functions and the Merck Foundation from 1999 to 2007.

In addition to his position with PhRMA, Frazier sits on the boards of Weill Cornell Medical College and Graduate School of Medical Sciences, Exxon Mobil, the Pennsylvania State University and Cornerstone Christian Academy in Philadelphia.

Scangos was appointed CEO of Biogen in June 2010. He joined the company from Exelixis, where he was president and CEO since October 1996. From 1987 to 1996, Scangos held various positions at Bayer, including senior vice president of R&D, and president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s recombinant products. Previously, he was professor of biology at Johns Hopkins University.

Duato became worldwide chairman, pharmaceuticals, Johnson & Johnson, in January 2011.  Previously, Duato held the positions of company group chairman, the Americas, and company group chairman, Ortho Clinical Diagnostics. Duato joined Johnson & Johnson in 1989 in Janssen-Cilag Spain and later became managing director of Janssen-Cilag Italy. He then led Ortho Biotech Europe before relocating to the U.S. in 2002 as vice president for the Ortho Biotech Oncology Franchise. He was named president, Ortho Biotech Products, in 2005.

Castellani will step down as president and CEO of PhRMA after leading the association since September 2010. The search for Castellani’s successor will begin immediately and will be led by the PhRMA board's nominations and compensation committee. Korn Ferry has been retained to conduct the search.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing